VIP for Immune System: What the Evidence Shows
What human and animal studies show about VIP for immune system, how strong that evidence is, and what is still unproven.
- Strongest evidence
- Human RCT
- Human studies
- 4
- with an outcome for immune system, in our evidence file (PubMed search, 11 Oct 2026)
- Animal studies
- None found
- with an outcome for immune system, in our evidence file (PubMed search, 11 Oct 2026)
- Studies we summarised
- 5
- with an outcome for immune system
Evidence for immune system
Each row is an outcome related to immune system from a published study, strongest design first. Animal and cell results are labelled and are not human results. User reports are not counted as evidence here.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Time to discharge | Average time to discharge was 7.8 days on inhaled aviptadil versus 10 days on placebo (p = 0.049). | Human RCTn = 80 | Medical principles and practice 2025, PMID 39870064 |
| Day-90 ordinal outcome | Aviptadil did not significantly improve the day-90 outcome category. | Human RCTn = 461 | The Lancet. Respiratory medicine 2023, PMID 37348524 |
| Mortality to day 90 | Day-90 mortality was 38% on aviptadil and 36% on placebo with no significant difference. | Human RCTn = 461 | The Lancet. Respiratory medicine 2023, PMID 37348524 |
| Primary endpoint (alive and free of respiratory failure at day 60) | The primary endpoint was not met (OR 1.6, 95% CI 0.86-3.11). | Human RCTn = 196 | Critical care medicine 2022, PMID 36044317 |
| 60-day survival (secondary) | A secondary survival analysis showed two-fold odds of survival (OR 2.0, p = 0.035). | Human RCTn = 196 | Critical care medicine 2022, PMID 36044317 |
| TNF-alpha production and regulatory T cells | Nebulized VIP was well tolerated and reduced TNF-alpha production by lung lavage cells in sarcoidosis. | Human uncontrolled trialn = 20 | American journal of respiratory and critical care medicine 2010, PMID 20442436 |
| Survival odds vs placebo | The two RCTs together showed no survival benefit (OR 1.01, p = 0.93). | Meta-analysisn = 665 | Indian journal of critical care medicine 2025, PMID 41368449 |
VIP and immune system are not in our PubMed count ledger yet; the rows above come from our evidence file (PubMed search, 11 Oct 2026). Grades follow our .
How strong is it?
A human randomized trial outweighs any number of animal studies. Animal and cell results show a mechanism worth testing, not that it works in people.
The immune system in plain terms
MedlinePlus describes the immune system as a complex network of cells, tissues and organs.[6]
COVID-19 respiratory failure trials
In a 196-patient trial of intravenous aviptadil, the primary endpoint of being alive and free of respiratory failure at day 60 did not reach statistical significance.[3]
In the larger trial, 38% on aviptadil and 36% on placebo had died by day 90.[2]
In the inhaled-aviptadil trial the death rate was 5.1% against 12.2% on placebo, a secondary finding.[1]
Immune-regulation signals
A sarcoidosis study concluded it was the first to show an immunoregulatory effect of VIP in humans.[4]
The ARDS meta-analysis said aviptadil may have a physiological role in improving oxygenation and reducing inflammation, but current evidence does not indicate a significant survival benefit.[5]
Other peptides people research for immune system
All peptides for immune system, comparedCommon questions
Does VIP help with immune system?
The strongest study we summarise for immune system is human rct evidence, across 5 studies with an outcome for immune system. A trial result is not an approval; see the legal status.
Is VIP approved for immune system?
No. VIP is not FDA approved for any use, including immune system.
What is the best peptide for immune system?
There is no single answer. Our immune system overview compares each candidate by evidence grade and legal status rather than by popularity.
Does VIP boost the immune system?
No study cited measures a general immune boost; VIP studies looked at COVID-19 outcomes and cytokine production in sarcoidosis.[4]
More on VIP
Sources
- 1Inhaled Aviptadil Is a New Hope for Recovery of Lung Damage due to COVID-19.Medical principles and practice : international journal of the Kuwait University, Health Science Centre · 2025PMID 39870064Accessed 2 Oct 2026
- 2Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial.The Lancet. Respiratory medicine · 2023PMID 37348524Accessed 2 Oct 2026
- 3The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.Critical care medicine · 2022PMID 36044317Accessed 2 Oct 2026
- 4Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis.American journal of respiratory and critical care medicine · 2010PMID 20442436Accessed 2 Oct 2026
- 5Aviptadil Therapy in Acute Respiratory Distress Syndrome Patients: A Systematic Review and Meta-analysis.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2025PMID 41368449Accessed 2 Oct 2026
- 6Official web pageOfficial web page · web page
Found an error? Report a correction.